Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension - Test2 - elhamkhani - TriplyDB

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

http://www.wikidata.org/entity/Q26748049

about

Neuronal nitric oxide synthase in hypertension - an update The potential of stimulating nitric oxide formation in the treatment of hypertension.Impact of the NO-Sensitive Guanylyl Cyclase 1 and 2 on Renal Blood Flow and Systemic Blood Pressure in Mice.

P2860

Q28077204-04C843F9-DCD7-4D7D-A7E9-DC2BCECE2D6D Q39198264-BC6A35B3-D351-4691-B1B7-EFAA816773AB Q55266424-B759A336-58D0-4C8C-B337-0344400CA788

P2860

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

http://www.wikidata.org/entity/Q26748049

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@ast

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@en

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@nl

type

label

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@ast

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@en

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@nl

prefLabel

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@ast

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@en

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@nl

P1433

Q26748049-EBAF1870-3557-45F1-A0FB-D0AE35B8276F

P1476

Q26748049-2AC9E76C-546F-4274-BDC3-383959AF6FE4

P2093

Q26748049-37EAB608-C7D0-456F-90B1-836DAD4B0C98

Q26748049-BDA8409B-DD00-4B90-A117-AA719914ED8D

P275

Q26748049-0E379FC8-1A40-4D61-9F9C-B60AC9C4C4FF

P2860

Q26748049-04DEEC2A-B108-471E-A20E-02112F180DCB

Q26748049-09469F42-EFFD-4001-B79C-673B5E36A158

Q26748049-09596E6F-8AB0-4D21-9BAC-652B81A9947B

Q26748049-12707537-BD60-43D5-8BC9-340B5B800DAD

Q26748049-187B39F7-A301-4C51-8DD1-F94A1104C180

Q26748049-19B8F0C4-931F-4B50-BAC8-2010F3A82EA4

Q26748049-1FAD48C6-CCBB-4747-B0A8-25B525679320

Q26748049-20B5DE24-DD20-44C0-86AD-0891130FD8C1

Q26748049-274302EE-170F-40F6-B4DC-F6C77008BE84

Q26748049-2A28BF7A-C53C-4690-A5F4-D279074612D7

P2888

Q26748049-D427E1BB-3485-46A9-A4AB-555E7BD7624C

P304

Q26748049-703C76E7-C764-49F2-84A8-E51686602EB8

P31

Q26748049-767C89F5-BF5E-45C0-BF40-872D9A6DC583

Q26748049-92E7549A-63C2-4114-9892-A8D976D017AE

P3181

Q26748049-267F02C3-8F33-4D11-9B67-DF239BD000DA

P356

Q26748049-677A7F3B-42CD-4654-8BFB-64B85B7D7732

P407

Q26748049-64801AB6-B80F-4A6F-9370-B141DC46DB5B

P433

Q26748049-80382EFE-4677-4273-AF9C-91F02A5A0DD4

P478

Q26748049-48F7759A-E844-42C9-9542-A7664B0D0135

P5008

Q26748049-103599D3-AB8E-4311-8C1F-5751B64F1BE2

P577

Q26748049-5423FADE-1F77-4325-91F2-F831FC6CA319

Q26748049-56C19418-8013-440C-B7EA-42404F9130C6

P5875

Q26748049-B0060BB9-5F0B-4F69-9C58-1CD6897FA2D9

P6179

Q26748049-6F8D014C-DE60-4A5B-B76F-4225267889E5

P698

Q26748049-BD3CB7AD-AF54-41BC-AA40-A35D2F91A8E2

P921

Q26748049-257419AE-8812-4D2E-84B2-3257DA2F14A7

Q26748049-4C7E826F-FE47-46BE-866E-0927D84E8744

Q26748049-A1DE0232-9A9C-4992-BB8D-EC637928ACE7

Q26748049-A3665FAA-8F5F-43B4-ABBB-907568C69A75

Q26748049-D77B8038-DCE1-40AD-9B8D-F2CEFF1FB584

P932

Q26748049-BCC35076-2096-40BE-85B5-5B3FEA5D8461

P3181

P356

S11906-016-0646-5

P1433

Current Hypertension Reports

P1476

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension

@en

P2093

Evanthia Mergia

http://www.w3.org/2001/XMLSchema#string

Johannes Stegbauer

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

Functional properties of a naturally occurring isoform of soluble guanylyl cyclase

Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system

Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

AT₂ receptor activation induces natriuresis and lowers blood pressure.

Endothelium-derived nitric oxide supports renin cell recruitment through the nitric oxide-sensitive guanylate cyclase pathway.

P2888

s11906-016-0646-5

P304

39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4927946

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11906-016-0646-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

301314057

http://www.w3.org/2001/XMLSchema#string

P6179

1033253920

http://www.w3.org/2001/XMLSchema#string

P698

27079836

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

arterial hypertension

P932

4832004

http://www.w3.org/2001/XMLSchema#string